Two decades ago, a person diagnosed with HIV infection confronted the very real possibility of death within a few years, if not sooner. The transformation of HIV from a terminal condition to a chronic, albeit manageable, ailment is largely the result of increasingly efficacious anti-retroviral therapy (ART). ART’s efficacy has manifested in the “graying” of the HIV epidemic. Indeed, by 2015, 50 percent of persons living with HIV/AIDS in the United States are expected to be ≥ 50 years of age and that number is expected to rise to 70 percent by 2020. Prevalence data show that in 2011, 45 percent of the 114,000 people living with HIV in New York City were already 50 years of age or older. During the past decade, there has been an average annual increase of 2 percent in the number of people ≥ 50 years of age in the U.S. living with HIV/AIDS (CDC, 2013).